Vyome Holdings, Inc.

As reflected in the post shared by an oncology healthcare professional, malignant fungating wounds can have a profound emotional impact not only on patients and families, but also on the healthcare professionals who care for them. Symptoms like severe malodor and pain can lead to social isolation, emotional distress, and loss of dignity, and yet there are currently no FDA-approved therapies specifically addressing these symptoms. At Vyome Holdings, we are advancing VT-1953, an investigational program that has completed Phase 2 clinical development, with the goal of improving quality of life for patients living with malignant fungating wounds. @VyomeInc $HIND #Oncology #WoundCare #Biotech

Patients living with malignant fungating wounds face a huge unmet need, with symptoms like severe malodor and pain profoundly affecting quality of life. Dr. Charles Tilley discusses the lack of FDA-approved therapies specifically indicated for these wounds and why advancing symptom management remains critical. #CancerCare #WoundCare #HealthcareInnovation

pharmaleaders.tv/vyome-seals-st… @VyomeInc @newvenkat #VyomeStrikesDeal #ImpetisBiosciences #TATAEnterprise #BiotechInnovation #GlobalMarketOpportunity #57BillionMarket

@VyomeInc $HIND expands into one of the largest opportunities in immunology through a highly capital efficient licensing deal with Impetis Biosciences, a @TataCompanies entity. Selective JAK inhibitor assets targeting a potential ~$57B TAM. No upfront payments. No development milestones. Royalty only post commercialization. Future development planned through non dilutive pathways while maintaining sharp focus on VT1953. Scientific depth. Capital discipline. Global innovation corridors. #Biotech #Immunology #NASDAQ #Innovation

Some of the hardest parts of advanced cancer aren’t always visible. Dr. Charles Tilley, WOCN and hospice nurse practitioner, discusses the emotional toll malignant fungating wounds can have on patients living with advanced cancer. Awareness matters. Support matters. Better therapies matter. #MentalHealthAwarenessWeek #CancerCare #WoundCare #PatientAdvocacy

$HIND

$HIND

Malignant fungating wounds (MFW) are among the most challenging conditions in advanced cancer care, with a profound physical and emotional toll on patients, families, and caregivers. In this video, Dr. Charles Tilley, PhD, RN, CWOCN, a hospice nurse practitioner and palliative wound care specialist, shares his frontline, independent perspective on the realities of caring for patients with MFWs and the importance of improving supportive care options. Today, there are no FDA-approved therapies specifically for MFW symptoms. At Vyome, we are developing VT-1953, an investigational therapy, as a potential first-in-class approach to target these symptoms. #PalliativeCare #Oncology #WoundCare #Biotech

This Mental Health Awareness Month, we recognize a patient experience that often goes unseen. Malignant fungating wounds impact more than the body, with patients facing persistent malodor and pain, which can lead to social isolation, anxiety, and loss of dignity. The psychological burden can be as significant as the physical symptoms, underscoring the need for more holistic care. Currently, there are no approved FDA therapies for treating symptoms of malignant fungating wounds. We are advancing VT-1953, a Phase 2–completed investigational candidate, with the goal of addressing key symptoms associated with these wounds and, in turn, supporting overall patient mental and emotional well-being. #MentalHealthAwarenessMonth #PatientCare #Oncology #Biotech

Biotech is reopening in 2026. But the playbook has changed. Q1 tells the story: $1.7–1.8B IPOs (best since 2021) $10B+ follow-ons (~3x YoY) ~70%+ jump in total financings Capital is back. But it’s not chasing stories. It’s rewarding: Clean cap tables Tight cost discipline Smart, fast clinical design Real regulatory clarity This is not the hype cycle. It’s the execution cycle. For public biotech: Clarity drives valuation. Discipline sustains it. The next winners won’t be the loudest. They’ll be the most predictable. #Biotech2026 #BiotechInvesting #CapitalMarkets #HealthcareInnovation

Vyome is pleased to share Phase 2 clinical data for VT-1953, an investigational therapy targeting symptom burden of malignant fungating wounds (MFW), at prestigious #AACR2026. MFW remains an area of significant unmet need with no FDA-approved therapies. The study demonstrated a reduction in MFW-associated malodor over 14 days vs placebo. #Biotech #Oncology #LifeSciences #WoundCare

$HIND

$HIND

$HIND

$HIND

Volatility doesn’t change our focus. We’re executing against clear clinical and regulatory priorities with a long-term mindset. Short-term trading moves don’t alter the work ahead or our commitment to disciplined progress and transparency on VT 1953 program. @VyomeInc $HIND

The next phase of biopharma value won’t be driven by hype—but by execution, cost discipline, and patient impact. Deloitte’s 2026 Life Sciences Executive Outlook shows leaders prioritizing R&D productivity, capital discipline, and focus. Do fewer things. Do them right. #Biotech #LifeSciences #ExecutionMatters #CapitalDiscipline

Malignant Fungating Wounds (MFWs), associated with late stage cancer, has a $2.2B Total Addressable Market. But there are ZERO FDA-approved drugs for them. VT-1953 aims to be the first. With successful Phase 2 data in hand, the asset is projected to be worth $1B upon Phase 3 completion. $HIND

Some diseases don’t just cause pain — they take away dignity. Symptoms of Malignant fungating wounds have no FDA-approved treatments today. Seeing independent analysts recognize the promise of VT-1953 after Phase 2 isn’t about only valuation — it’s about validating a deeply ignored unmet need. Sometimes biotech is about healing people, not just diseases. #Biotech #UnmetNeed #ImmunoInflammation #Oncology @VyomeInc $HIND

@newvenkat Curious how others think about integrating symptom burden endpoints earlier in oncology development, especially where no approved therapies exist today.